However, a study using lupus-prone mice demonstrated that pharmacological inhibition and genetic ablation of IL-17A did not improve clinical manifestations, including survival rate, glomerulonephritis, and autoantibody production (22). Here, IL17A is linked to systemic lupus erythematosus.